Metronidazole Topical Cream, 0.75% FOR TOPICAL USE ONLY (NOT FOR OPHTHALMIC USE)

Manufacturer
Preferred Pharmaceuticals Inc.
Effective date
2026-07-08
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
weekly-update
Hydrated at
2026-07-17 21:45:09

Label at a glance#

ProductMetronidazole
Active ingredientMETRONIDAZOLE
Label structure10 sections

Indications and uses

Metronidazole topical cream is indicated for topical application in the treatment of inflammatory papules and pustules of rosacea.

Dosage and administration

Apply and rub in a thin layer of metronidazole topical cream twice daily, morning and evening, to entire affected areas after washing. Areas to be treated should be washed with a mild cleanser before application. Patients may use cosmetics after application of metronidazole topical cream.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Metronidazole topical cream contains metronidazole, USP, at a concentration of 7.5 mg per gram (0.75%) in an emollient cream consisting of benzyl alcohol, emulsifying wax, glycerin, isopropyl palmitate, purified water, sorbitol solution, lactic acid and sodium hydroxide to adjust pH.

Metronidazole is a member of the imidazole class of antibacterial agents and is classified therapeutically as an antiprotozoal and anti-bacterial agent. Chemically, metronidazole is 2-methyl-5-nitro-1H-imidazole-1-ethanol. The molecular formula is C6H9N3O3 and molecular weight is 171.15.

Metronidazole is represented by the following structural formula:

DESCRIPTION
DESCRIPTION

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

The mechanisms by which metronidazole acts in the treatment of rosacea are unknown, but appear to include an anti-inflammatory effect.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Metronidazole topical cream is indicated for topical application in the treatment of inflammatory papules and pustules of rosacea.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Metronidazole topical cream is contraindicated in individuals with a history of hypersensitivity to metronidazole, or other ingredients of the formulation.

PRECAUTIONS

PRECAUTIONS SECTION

General

SPL UNCLASSIFIED SECTION

Topical metronidazole has been reported to cause tearing of the eyes. Therefore, contact with the eyes should be avoided. If a reaction suggesting local irritation occurs, patients should be directed to use the medication less frequently or discontinue use. Metronidazole is a nitroimidazole and should be used with care in patients with evidence of, or history of blood dyscrasia.

Information for patients

INFORMATION FOR PATIENTS SECTION

This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.

Drug Interactions

DRUG INTERACTIONS SECTION

Oral metronidazole has been reported to potentiate the anticoagulant effect of warfarin and coumarin anticoagulants, resulting in a prolongation of prothrombin time. The effect of topical metronidazole on prothrombin time is not known.

Carcinogenes is, mutagenes is, impairment of fertility

SPL UNCLASSIFIED SECTION

Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats but not in studies involving hamsters.

Metronidazole has shown evidence of mutagenic activity in several in vitro bacterial assay systems. In addition, a dose-response increase in the frequency of micronuclei was observed in mice after intraperitoneal injections and an increase in chromosome aberrations have been reported in patients with Crohn's disease who were treated with 200 mg/day to 1,200 mg/day of metronidazole for 1 months to 24 months.

However, no excess chromosomal aberrations in circulating human lymphocytes have been observed in patients treated for 8 months.

Pregnancy

PREGNANCY SECTION

Teratogenic effects

There are no adequate and well-controlled studies with the use of metronidazole topical cream in pregnant women. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral metronidazole in rats or mice. However, because animal reproduction studies are not always predictive of human response and since oral metronidazole has been shown to be a carcinogen in some rodents, this drug should be used during pregnancy only if clearly needed.

Nursing mothers

NURSING MOTHERS SECTION

After oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. Even though blood levels are significantly lower with topically applied metronidazole than those achieved after oral administration of metronidazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

In controlled clinical trials, the total incidence of adverse reactions associated with the use of metronidazole topical cream was approximately 10%. Skin discomfort (burning and stinging) was the most frequently reported event followed by erythema, skin irritation, pruritus and worsening of rosacea.

All individual events occurred in less than 3% of patients. The following additional adverse experiences have been reported with the topical use of metronidazole: dryness, transient redness, metallic taste, tingling or numbness of extremities and nausea.

To report SUSPECTED ADVERSE REACTIONS, contact Viona Pharmaceuticals Inc. at 1-888-304-5011 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Apply and rub in a thin layer of metronidazole topical cream twice daily, morning and evening, to entire affected areas after washing.

Areas to be treated should be washed with a mild cleanser before application. Patients may use cosmetics after application of metronidazole topical cream.

HOW SUPPLIED

HOW SUPPLIED SECTION

Metronidazole topical cream, 0.75% is white to off-white homogeneous cream, free from lumps, free from gritty particles and foreign matter without phase separation and is supplied as follows:

45 gram aluminum tube

NDC 68788-8552-4

Storage conditions: Store at 20°C to 25°C (68ºF to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].

Call your doctor for medical advice about side effects. You may report side effects to Viona Pharmaceuticals Inc. at 1-888-304-5011 or FDA at 1-800-FDA-1088.

SPL UNCLASSIFIED

SPL UNCLASSIFIED SECTION

Manufactured by:

Zydus Lifesciences Ltd.

Changodar, Ahmedabad, India

Distributed by:

Viona Pharmaceuticals Inc.

Cranford, NJ 07016

Rev.: 01/23

Relabeled By: Preferred Pharmaceuticals Inc.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 68788-8552-4

Metronidazole Topical Cream, 0.75%

Rx only

45 g

Viona

Relabeled By: Preferred Pharmaceuticals Inc.

Metronidazole Topical Cream 0.75%
Metronidazole Topical Cream 0.75%

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
Data codeCode 12814973d32ce01-d498-47d9-b589-3b2b8c741524-02.jpg
Data codeQR Code14973d32ce01-d498-47d9-b589-3b2b8c741524-02.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
8ffb9b1d-3ed7-ba2e-677e-47d4d134fd55Product name520251024
7f6d14e0-4366-41bc-a4a9-b74c79a20e17Product name120250623
e6d321b0-0e5e-7da6-f043-92b6a91f00a1Product name520250515
e1aac33b-94ae-4ee9-905b-299f7263853bProduct name320250124
16642716-d28a-4f90-8dcb-3921cd8c8109Product name420240516
0be8e4ae-4d57-49f3-b3a9-e4728b4e8d15Product name120240313
dea2eded-d1e7-46bb-9a3d-f8dc20de6277Product name120190408
a5070875-62bb-61e1-fd46-8f7054197a40Product name820180215
0add4de9-d152-3375-3390-1123dddc5e3dProduct name120140508
33ca0fcc-1011-92dc-50a9-a383683eed1eProduct name120140508
53f39d9f-cd3f-04e1-c668-d4580719d57dProduct name120140508
a804000f-b74f-0b5d-d17b-aa767c286ddbProduct name120140508
a91ea265-6e02-c08f-93c8-686d54180529Product name120140508

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
68788-8552-4GM - Gram68788-85529433a944-27a5-417a-9d36-deb50ee7594c12024-01-04
72578-129-08GM - Gram72578-1297db5feda-08ab-4fef-b930-07d9640d815212023-09-05

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
68788-855268788-8552-4
72578-129

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
22025-01-15full-release2026-05-31 21:22:58

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A217128-001METRONIDAZOLEMETRONIDAZOLE0.75%CREAM / TOPICALBX2023-04-21

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A217128-001BX

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A217128-001METRONIDAZOLE0.75%CREAM / TOPICALBX2023-04-2184e616aacf4f…
2026-08-18 06:07:402026-07A217128-001METRONIDAZOLE0.75%CREAM / TOPICALBX2023-04-21caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A217128-001METRONIDAZOLE0.75%CREAM / TOPICALBX2023-04-21011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A217128-001METRONIDAZOLE0.75%CREAM / TOPICALBX2023-04-2131067a03dcf5…
2025-08-23 18:47 UTC2025-08A217128-001METRONIDAZOLE0.75%CREAM / TOPICALBX2023-04-216a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-21fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-21b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-2103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-212680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-215bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-21d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-21d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-2179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-21301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-211e350fbaab3a…
2024-05-31 18:47 UTC2024-05A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-218072bd15b7f6…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-216a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-211c564ffb4f44…
2023-12-20 04:57 UTC2023-12A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-21ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-21a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-219b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-21a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A217128-001METRONIDAZOLE0.75%CREAM / TOPICALAB2023-04-213f0d92c62455…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A217128-001METRONIDAZOLE0.75%CREAM / TOPICALBX2023-04-21a50c72e98297…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A217128-001BX184e616aacf4f…
2026-08-18 06:07:402026-07A217128-001BX1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A217128-001BX1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A217128-001BX131067a03dcf5…
2025-08-23 18:47 UTC2025-08A217128-001BX16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A217128-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A217128-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A217128-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A217128-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A217128-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A217128-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A217128-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A217128-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A217128-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A217128-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A217128-001AB18072bd15b7f6…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A217128-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A217128-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A217128-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A217128-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A217128-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A217128-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A217128-001AB13f0d92c62455…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A217128-001BX1a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
MetronidazoleMETRONIDAZOLEPreferred Pharmaceuticals Inc.59e53582-244a-4e9d-b18e-75dddc6a50522026-07-08Adverse reactionsExact identifier
ndc (package): 68788-8552-4
ndc (product): 68788-8552
ndc11 (package): 68788855204
spl id: 1969dc9c-4ced-498b-90a6-c027846b7aaf
spl set id: 59e53582-244a-4e9d-b18e-75dddc6a5052
MetronidazoleMETRONIDAZOLEViona Pharmaceuticals Inc93299502-6cb0-48a4-8190-50fef74bdbee2024-12-06Adverse reactionsExact identifier
ndc (product): 72578-129

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.